Genomic evolution of SARS-CoV-2 variants of concern underin vitroneutralising selection pressure following two doses of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine

Author:

Basile KerriORCID,Agius Jessica E.,Fong Winkie,McPhie Kenneth,Fennel Michael,Ko Danny,Heuston Linda,Lam ConnieORCID,Arnott Alicia,Chen Sharon C-A,Maddocks Susan,O’Sullivan Matthew V. N.,Dwyer Dominic E.,Sintchenko Vitali,Kok Jen,Rockett Rebecca J.,

Abstract

AbstractAimsTo explore viral evolution duringin vitroneutralisation using next generation sequencing, and to determine whether sera from individuals immunised with two doses of the Pfizer-BioNTech vaccine (BNT162b2) are as effective at neutralising the SARS-CoV-2 variant of concern (VOC) Delta (B 1.617.2) compared to the earlier lineages Beta (B.1.351) and wild-type (A.2.2) virus.MethodsUsing a live-virus SARS-CoV-2 neutralisation assay in Vero E6 cells we determined neutralising antibody titres (nAbT) in 14 participants (vaccine-naïve (n=2) and post-second dose of BNT162b2 vaccination (n=12), median age 45 years [IQR 29–65], median time after second dose = 21 days [IQR 19–28] against three SARS-CoV-2 strains: wild-type, Beta and Delta. The determination of nAbT was performed by visual inspection of cytopathic effect (CPE) and in-house quantitative reverse transcriptase real time quantitative polymerase chain reaction (RT-qPCR) to confirm SARS-CoV-2 replication. A total of 110 representative samples including inoculum, neutralisation breakpoints at 72 hrs, negative and positive controls underwent genome sequencing using the Respiratory Viral Oligo Panel version 2 (RVOP) (Illumina Inc. (San Diego, United States of America)) viral enrichment and short read sequencing using (Illumina Inc.San Diego, United States of America)(Figure 1).ResultsThere was a significant reduction in nAbT observed against the Delta and Beta VOC compared with wild-type, 4.4-fold (p= >0.0006) and 2.3-fold (p= 0.0140), respectively (Figure 2). Neutralizing antibodies were not detected in one vaccinated immunosuppressed participant nor the vaccine-naïve participants (n=2). The highest nAbT against the SARS-CoV-2 variants investigated was obtained from a participant who was vaccinated following SARS-CoV-2 infection 12 months prior (Table S1). Limited consensus level mutations occurred in the SARS-CoV-2 genome of any lineage duringin vitroneutralisation, however, consistent minority allele frequency variants (MFV) were detected in the SARS-CoV-2 polypeptide, spike (S) and membrane protein.DiscussionSignificant reductions in nAbT post-vaccination were identified, with Delta demonstrating a 4.4-fold reduction. The reduction in nAbT for the VOC Beta has been previously documented, however, limited data is available on vaccine evasion for the Delta VOC, the predominant strain currently circulating worldwide at the time. Studies in high incidence countries may not be applicable to low incidence settings such as Australia as nAbT may be significantly higher in vaccine recipients previously infected with SARS-CoV-2, as seen in our cohort. Monitoring viral evolution is critical to evaluate the impact of novel SARS-CoV-2 variants on vaccine effectiveness as mutational profiles in the sub-consensus genome could indicate increases in transmissibility, virulence or allow the development of antiviral resistance.

Publisher

Cold Spring Harbor Laboratory

Reference53 articles.

1. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

2. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

3. COVID-19 Advice for the Public: Getting Vaccinated, The World Health Organization. Acessed on 12 September 2022. Available at:Https://Www.Who.Int/Emergencies/Diseases/Novel-Coronavirus-2019/Covid-19-Vaccines/Advice.

4. Neutralizing Activity of BNT162b2-Elicited Serum

5. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3